Michael Severino, Tessera Therapeutics CEO

Af­ter rais­ing half a bil­lion dol­lars, a se­cre­tive biotech gives an ear­ly look at its gene edit­ing pipeline

A se­cre­tive biotech start­up de­vel­op­ing a new form of gene edit­ing is start­ing to give cu­ri­ous sci­en­tists a peek at its pipeline — with­out ful­ly di­vulging …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.